BioInvent International AB (BioInvent) discovers and develops antibody-based therapies for cancer treatment. The company's proprietary F.I.R.S.T technology platform facilitates the identification of therapeutic targets and the corresponding antibodies that bind to them, generating a strong pipeline of promising drug candidates.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

BioInvent's lead programs, BI-1808 (TNFR2 program) and BI-1206 (Fc?RIIB program) focus on strategically selected targets to enhance the efficacy of established immune therapies, including checkpoint inhibitors. The TNFR2 program aims to modulate regulatory T cells (Tregs) to promote the expansion of activated CD8+ cells for tumor eradication. This program has yielded two candidates: BI-1808, currently in Phase 1/2 studies, and BI-1910, which commenced clinical studies in December 2024. The Fc?RIIB program targets receptors on tumor cells and certain immune cells, with candidates BI-1206 and BI-1607 in Phase 2 and Phase 1 studies, respectively, designed to improve outcomes in hematologic and solid tumors. In FY2024, the company invested SEK439.8 million on its R&D activities, which grew by 17.3% YoY.